Radiopharmaceuticals integrate nuclear science with precision medicine, utilizing radioisotopes and biological molecules for targeted therapeutic and diagnostic applications. The global market is projected to expand from $7.9 billion in 2023 to $21.8 billion by 2033 due to their efficacy in cancer treatment and imaging. Isotopes like lutetium-177 have shown promising results in trials for neuroendocrine tumors and metastatic prostate cancer. However, supply chain challenges and a need for skilled professionals hinder patient access and treatment scalability.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.